Overview
- An international SickKids-led study of 611 tumors from 544 children and young adults used whole-genome sequencing plus detailed treatment records to link tumor mutations to specific therapies.
- About 15% of mutations in the relapsed tumors were clearly traced to four chemotherapies, with platinum drugs (cisplatin, carboplatin, oxaliplatin) accounting for most therapy-linked damage.
- Platinum-related mutation signatures can appear quickly after treatment, sometimes within three months, and strong platinum signatures often coincide with activation of genes tied to platinum resistance.
- Patients whose tumors carried strong platinum signatures had poorer outcomes on platinum therapy in both the pediatric cohort and independent adult datasets, though therapy-linked mutations do not always cause resistance.
- Researchers say the signatures could one day guide choices such as avoiding drug reuse, lowering doses, or early screening for resistant clones, but clinical validation and ethical carefulness are required before changing pediatric care.